Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Phase 2, Open-Label Study of (RS)-10-Propargyl-10-Deazaaminopterin (Pralatrexate) With Vitamin B12 and Folic Acid Supplementation in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma.

Trial Profile

A Multi-Center, Phase 2, Open-Label Study of (RS)-10-Propargyl-10-Deazaaminopterin (Pralatrexate) With Vitamin B12 and Folic Acid Supplementation in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Oct 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pralatrexate (Primary)
  • Indications Peripheral T-cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms PROPEL
  • Sponsors Acrotech Biopharma; Allos Therapeutics
  • Most Recent Events

    • 14 Dec 2021 Results of efficacy and safety of pralatrexate by using data from four trials including this trial presented at the 63rd American Society of Hematology Annual Meeting and Exposition
    • 01 Nov 2018 According to Servier media release, Servier Receives Health Canada Approval of FOLOTYN for the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma
    • 06 Dec 2016 Case match control analysis results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top